Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ZYME, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Zanidatamab (ZW25) FDA approved Nov 2024 · Ziihera |
Biliary Tract Neoplasms | Phase 3 · NCT05615818 | Recruiting |
| Tamoxifen | Breast Cancer | Phase 2 · NCT05035836 | Recruiting |
| Anti-MSLN/Anti-CD3 Bispecific Antibody ZW171 | Mesothelin-expressing Advanced Cancers | Phase 1 · NCT06523803 | Terminated |
| Anti-FRalpha Antibody-drug Conjugate ZW191 | Advanced Solid Tumors | Phase 1 · NCT06555744 | Active not recruiting |
| Anti-GPC3 Antibody-drug Conjugate ZW251 | Hepatocellular Carcinoma | Phase 1 · NCT07164313 | Recruiting |
| Zanidatamab Zovodotin (ZW49) | HER2-expressing Cancers | Phase 1 · NCT03821233 | Completed |
Also used in these trials (approved or third-party drugs, not ZYME's own candidates): Cisplatin, Trastuzumab, Niraparib, Neratinib, Ivosidenib, Gemcitabine Hydrochloride, Futibatinib, Encorafenib, Binimetinib, Letrozole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ZYME holds $100.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $28M/quarter from operations, an estimated runway of 10.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZYME files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| EcoR1 Capital, LLC Director, 10% owner |
Insider | 22,970,388 | 33.28% | 2025-11-16 |
| Rubric Capital Management LP | Institution (13G, 5%+) | 7,000,000 | 10.14% | 2026-03-31 |
| Blackrock Inc. | Institution (13F) | 4,212,745 | 6.10% | 2026-09-30 |
| Perceptive Advisors LLC | Institution (13G, 5%+) | 3,974,579 | 5.76% | 2026-04-08 |
| BVF Inc. | Institution (13F) | 3,464,142 | 5.02% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 3,236,915 | 4.69% | 2026-09-30 |
| BNP Paribas Asset Management Holding S.A | Institution (13F) | 1,781,031 | 2.58% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 1,558,998 | 2.26% | 2026-09-30 |
| Assenagon Asset Management S.A. | Institution (13F) | 1,508,069 | 2.18% | 2026-09-30 |
| Citadel Advisors Llc | Institution (13F) | 1,192,391 | 1.73% | 2026-09-30 |
| Gregory Austin Ciongoli Director · +81,200 options |
Insider | 493,500 | 0.71% | 2025-08-11 |
| Kenneth Galbraith Chair & CEO, Director · +582,000 options |
Insider | 226,842 | 0.33% | 2026-01-12 |
Share count 69,030,691 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-13 filed 2026-11-16 |
Moore Paul Andrew |
Option exercise (M) | 25,000 | $5.82 | 73,497 |
| 2026-11-13 filed 2026-11-16 |
Moore Paul Andrew |
Sale (S) | 7,367 | $26.14 | 66,130 |
| 2026-11-13 filed 2026-11-16 |
Moore Paul Andrew |
Sale (S) | 7,374 | $26.09 | 58,756 |
| 2026-11-13 filed 2026-11-16 |
Moore Paul Andrew |
Sale (S) | 25,000 | $26.04 | 33,756 |
| 2026-11-13 filed 2026-11-16 |
Moore Paul Andrew |
Option exercise (M) | 25,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-08-25 | Ziihera | NDA | +25.9% | -4.5% | — |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZYME and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →